Endo faces poor prospects from weak branded and generic drug segments and a high debt burden.
We plan to modestly raise our fair value estimate for no-moat Endo after slightly better-than-expected second-quarter results thanks to ongoing strength of the company's generic injectable products and Xiaflex. The beneficial product mix and efficiency efforts improved gross margin and selling, general, and administrative expense, offset partially by higher research and development spending. Management slightly raised its year-end top- and bottom-line outlook, and we intend to raise our revenue ...
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.